{'output': [['GenMark Diagnostics', 'ORG', 'Provide', 'Preliminary Operational and Financial Results', 'EVENT'], ['GenMark Diagnostics', 'ORG', 'Operate_In', 'Molecular Diagnostic Testing Systems Industry', 'SECTOR'], ['GenMark Diagnostics', 'ORG', 'Expect', 'Issue Full 2017 Financial Results and 2018 Guidance', 'EVENT'], ['GenMark Diagnostics', 'ORG', 'Launch', 'ePlex NP', 'PRODUCT'], ['ePlex', 'PRODUCT', 'Contribute', 'Fourth Quarter Placements', 'EVENT'], ['ePlex', 'PRODUCT', 'Place', '49 ePlex Analyzers', 'PRODUCT'], ['ePlex', 'PRODUCT', 'Finish', 'Quarter with Installed Base of 196 ePlex Analyzers', 'EVENT'], ['ePlex', 'PRODUCT', 'Initiate', 'First of Three Clinical Trials for the ePlex BCID Family of Panels', 'EVENT'], ['Hany Massarany', 'PERSON', 'Say', 'Commercial Teams Delivered Another Quarter of Strong ePlex Placements', 'EVENT'], ['Hany Massarany', 'PERSON', 'Add', 'Recent Launch of ePlex NP Improve Patient Access to Multiplex Molecular Diagnostics', 'EVENT'], ['ePlex', 'PRODUCT', 'Designed', 'Support Broad Range of Molecular Diagnostic Tests', 'EVENT'], ['ePlex', 'PRODUCT', 'Optimize', 'Laboratory Efficiency', 'EVENT'], ['ePlex', 'PRODUCT', 'Address', 'Broad Range of Infectious Disease Testing Needs', 'EVENT'], ['GenMark Diagnostics', 'ORG', 'Make', 'Changes to Optimize Approach in Europe', 'EVENT'], ['GenMark Diagnostics', 'ORG', 'Have', 'Strength of Sales Funnel', 'EVENT'], ['GenMark Diagnostics', 'ORG', 'Subject', 'Further Internal Review and Audit by Companyâ€™s External Auditors', 'EVENT'], ['GenMark Diagnostics', 'ORG', 'Issue', 'Full 2017 Financial Results and 2018 Guidance', 'EVENT'], ['GenMark Diagnostics', 'ORG', 'Describe', 'Risks and Uncertainties', 'EVENT'], ['GenMark Diagnostics', 'ORG', 'Assume', 'No Responsibility to Update or Revise Any Forward-Looking Statements', 'EVENT'], ['Lynn Pieper Lewis or Leigh Salvo', 'PERSON', 'Serve', 'Investor Relations Contact', 'EVENT']]}